PepGen (NASDAQ:PEPG) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of PepGen (NASDAQ:PEPG) from a hold rating to a sell rating in a report published on Saturday morning,Wall Street Zen reports.

Several other research analysts also recently commented on the stock. Craig Hallum started coverage on shares of PepGen in a report on Tuesday, June 16th. They issued a “buy” rating and a $11.00 target price on the stock. Weiss Ratings raised shares of PepGen from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 22nd. Finally, HC Wainwright restated a “buy” rating on shares of PepGen in a report on Wednesday, September 9th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $11.40.

PepGen Stock Down 5.0%

NASDAQ:PEPG opened at $2.49 on Friday. PepGen has a 12 month low of $1.31 and a 12 month high of $7.80. The firm has a market cap of $172.46 million, a price-to-earnings ratio of -1.90 and a beta of 2.01. The company’s 50 day moving average is $2.82 and its 200-day moving average is $2.20.

PepGen (NASDAQ:PEPG) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02. Research analysts predict that PepGen will post -1.11 EPS for the current fiscal year.

Institutional Trading of PepGen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Group One Trading LLC acquired a new stake in shares of PepGen in the first quarter worth $77,000. Seven Fleet Capital Management LP acquired a new position in PepGen during the 1st quarter valued at $105,000. Rangeley Capital LLC raised its stake in PepGen by 88.1% during the 1st quarter. Rangeley Capital LLC now owns 68,096 shares of the company’s stock valued at $121,000 after purchasing an additional 31,896 shares during the last quarter. Persistent Asset Partners Ltd acquired a new stake in PepGen in the 2nd quarter worth $171,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of PepGen during the 2nd quarter worth about $202,000. Institutional investors and hedge funds own 58.01% of the company’s stock.

PepGen Company Profile

PepGen Inc is a clinical-stage biotechnology company developing RNA-based therapeutics for severe neuromuscular and genetic diseases. The company’s programs are designed to address conditions caused by genetic mutations by selectively modifying or restoring the production of disease-related proteins.

PepGen’s technology platform, Enhanced Delivery Oligonucleotide (EDO), uses peptide-conjugated phosphorodiamidate morpholino oligomers to improve the delivery of therapeutic oligonucleotides into muscle and other tissues.